Padua Score Calculator
Calculate padua score quickly with our cardiovascular system tool. Get results based on evidence-based formulas with clear explanations.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
Formula
Padua Score = Sum of weighted risk factors (range 0-20)
Each risk factor is assigned a specific weight: Active cancer (3), Previous VTE (3), Reduced mobility (3), Known thrombophilia (3), Recent trauma/surgery (2), Age >= 75 (1), Heart/respiratory failure (1), Acute MI/stroke (1), Acute infection (1), Obesity BMI >= 30 (1), Hormonal therapy (1). Total score >= 4 indicates high risk for VTE.
Worked Examples
Example 1: High-Risk Medical Patient
Problem:A 78-year-old patient admitted with pneumonia has active cancer (on chemotherapy), reduced mobility (bed rest), and BMI of 33. Calculate the Padua Score.
Solution:Active cancer: +3 points Reduced mobility (bed rest >= 3 days): +3 points Age >= 75 years: +1 point Acute infection (pneumonia): +1 point Obesity (BMI >= 30): +1 point Total Padua Score = 3 + 3 + 1 + 1 + 1 = 9 points
Result:Padua Score: 9 (High Risk) | VTE Risk: ~11% | Pharmacological prophylaxis recommended
Example 2: Low-Risk Medical Patient
Problem:A 55-year-old patient admitted with controlled diabetes has no immobility, no cancer history, and BMI of 27. Calculate the Padua Score.
Solution:No active cancer: 0 points No previous VTE: 0 points No reduced mobility: 0 points No thrombophilia: 0 points No recent trauma/surgery: 0 points Age < 75: 0 points No heart/respiratory failure: 0 points No acute MI/stroke: 0 points No acute infection: 0 points Not obese: 0 points No hormonal therapy: 0 points Total Padua Score = 0 points
Result:Padua Score: 0 (Low Risk) | VTE Risk: ~0.3% | Routine prophylaxis not recommended
Frequently Asked Questions
What is the Padua Prediction Score and what does it assess?
The Padua Prediction Score is a validated risk assessment model developed in 2010 by Barbar and colleagues at the University of Padua, Italy, specifically designed to evaluate the risk of venous thromboembolism (VTE) in hospitalized medical patients. Unlike surgical risk assessment tools, the Padua Score addresses the unique thrombotic risk factors present in acutely ill medical patients. It assigns weighted points to 11 risk factors, with total scores ranging from 0 to 20. Patients scoring 4 or higher are classified as high risk with approximately 11% VTE incidence during hospitalization, while those scoring below 4 are classified as low risk with approximately 0.3% incidence. This stratification helps clinicians make evidence-based decisions about pharmacological thromboprophylaxis in medical inpatients.
How is the Padua Score different from other VTE risk assessment tools?
The Padua Score is specifically designed for medical inpatients, distinguishing it from surgical risk models like the Caprini Score. While surgical patients have well-established risk stratification based on procedure type and duration, medical patients present a more heterogeneous population requiring different risk factors. The Padua Score was validated in a prospective cohort study of 1,180 medical patients and demonstrated excellent discrimination between high-risk and low-risk groups. Other medical VTE risk tools include the IMPROVE score, which incorporates additional variables like D-dimer levels and lower extremity paralysis. The Geneva Risk Score is another alternative but was developed primarily for outpatients. Current ACCP and NICE guidelines recommend using validated risk assessment models like the Padua Score for medical patients.
What are the highest-weighted risk factors in the Padua Score?
Four risk factors in the Padua Score carry the maximum weight of 3 points each: active cancer, previous VTE, reduced mobility, and known thrombophilic condition. Active cancer includes patients with local or distant metastases, those who received chemotherapy or radiation therapy within the past 6 months, or those with cancer not in complete remission. Previous VTE encompasses any history of deep vein thrombosis or pulmonary embolism, as recurrence risk remains elevated. Reduced mobility is defined as anticipated bed rest with bathroom privileges for at least 3 days. Known thrombophilia includes conditions such as Factor V Leiden, prothrombin gene mutation, antithrombin deficiency, protein C or S deficiency, and antiphospholipid syndrome. Any single one of these high-weight factors combined with one additional point-bearing factor triggers high-risk classification.
What thromboprophylaxis is recommended for high-risk Padua Score patients?
Patients classified as high risk by the Padua Score (total score 4 or greater) should receive pharmacological thromboprophylaxis unless contraindicated. The recommended options include low-molecular-weight heparin (LMWH) such as enoxaparin 40 mg subcutaneously daily, unfractionated heparin (UFH) 5000 units subcutaneously every 8 or 12 hours, or fondaparinux 2.5 mg subcutaneously daily. LMWH is generally preferred due to once-daily dosing, more predictable pharmacokinetics, and lower risk of heparin-induced thrombocytopenia. Prophylaxis should be continued throughout the hospitalization and potentially beyond discharge in selected patients with persistent risk factors. Mechanical prophylaxis with graduated compression stockings or intermittent pneumatic compression devices should be used when pharmacological prophylaxis is contraindicated due to active bleeding or high bleeding risk.
What contraindications exist for pharmacological VTE prophylaxis in medical patients?
Several absolute and relative contraindications must be considered before initiating pharmacological thromboprophylaxis. Absolute contraindications include active major bleeding, severe uncontrolled hypertension, recent hemorrhagic stroke within the past 2 weeks, severe thrombocytopenia with platelet count below 25,000 per microliter, and known hypersensitivity to heparin products. Relative contraindications include hepatic failure with coagulopathy, active peptic ulcer disease, recent surgery with high bleeding risk, and intracranial lesions at risk for hemorrhage. When these contraindications exist, mechanical prophylaxis with intermittent pneumatic compression devices is recommended as an alternative. The bleeding risk should be assessed using validated tools such as the IMPROVE Bleeding Risk Score, which helps balance the benefits of VTE prevention against the risk of anticoagulant-related hemorrhage.
How does immobility contribute to venous thromboembolism risk?
Immobility is one of the strongest risk factors for VTE and carries 3 points in the Padua Score because it directly contributes to all three components of Virchow triad. Venous stasis occurs when the calf muscle pump is inactive, leading to pooled blood in the deep venous system of the lower extremities. This stasis promotes endothelial activation and creates a prothrombotic microenvironment. Studies have shown that hospitalized medical patients on bed rest have a 3-fold increased risk of DVT compared to ambulatory patients. Even partial immobility, such as being confined to a bed with bathroom privileges, significantly elevates risk. The risk increases with duration of immobility, with the greatest VTE incidence occurring after 3 or more days of reduced mobility. Early mobilization programs have been shown to reduce VTE rates and are recommended as part of comprehensive thromboprophylaxis strategies.
What is the relationship between cancer and venous thromboembolism?
Cancer is a major prothrombotic state that increases VTE risk by 4 to 7 times compared to the general population. Malignant cells produce tissue factor, cancer procoagulant, and inflammatory cytokines that activate the coagulation cascade and promote thrombus formation. The risk varies significantly by cancer type: pancreatic, brain, ovarian, and hematologic malignancies carry the highest risk, while prostate and breast cancers have relatively lower risk. Chemotherapy further increases VTE risk by 2 to 6 times through endothelial damage, reduced anticoagulant protein levels, and increased tissue factor expression. Central venous catheters and surgery add additional risk in cancer patients. The Padua Score assigns 3 points for active cancer, reflecting this substantial risk. Cancer-associated VTE is treated differently from non-cancer VTE, with LMWH or direct oral anticoagulants preferred over warfarin for therapeutic anticoagulation.
How should VTE prophylaxis be managed in patients with renal insufficiency?
Renal insufficiency complicates VTE prophylaxis because several anticoagulants are cleared through the kidneys, raising the risk of drug accumulation and bleeding. For patients with creatinine clearance below 30 mL per minute, dose adjustments are necessary. Enoxaparin should be reduced to 30 mg daily (from the standard 40 mg), or unfractionated heparin can be used as it does not rely on renal clearance. Fondaparinux is contraindicated when creatinine clearance is below 30 mL per minute due to excessive accumulation. Anti-Xa levels can be monitored when using LMWH in patients with severe renal impairment to ensure appropriate dosing. Patients on hemodialysis require individualized assessment, as they have both increased bleeding and thrombotic risks. The Padua Score does not specifically account for renal function, but bleeding risk assessment tools should be applied alongside it to optimize the risk-benefit ratio of prophylaxis.
What is extended-duration thromboprophylaxis and when is it considered?
Extended-duration thromboprophylaxis refers to continuing anticoagulant prophylaxis beyond hospital discharge, typically for 2-6 weeks. The rationale is that many VTE events in medical patients occur after discharge when risk factors such as reduced mobility, active illness, and cancer persist. The EXCLAIM, ADOPT, and MAGELLAN trials evaluated extended prophylaxis with different agents and showed reductions in VTE events but increased bleeding complications. Current guidelines suggest considering extended prophylaxis in selected high-risk patients, particularly those with active cancer, prolonged immobility, or multiple risk factors persisting at discharge. The MARINER trial evaluated rivaroxaban for 45 days post-discharge in high-risk medical patients and showed a trend toward VTE reduction. Individualized risk-benefit assessment is essential, weighing the patient specific VTE risk against bleeding risk before recommending extended prophylaxis.
How reliable is the Padua Score in different patient populations?
The Padua Score has been validated in several external cohorts with generally consistent performance, though some limitations exist. The original validation study in Italian medical patients showed excellent discrimination, with high-risk patients having a 37-fold greater VTE incidence than low-risk patients. Subsequent studies in different healthcare systems and populations have confirmed its clinical utility, though sensitivity and specificity vary. The score may underestimate risk in certain populations including critically ill ICU patients, patients with central venous catheters, and those with inflammatory bowel disease flares. It also does not account for some emerging risk factors such as COVID-19 infection, which dramatically increases VTE risk. In Asian populations, where baseline VTE incidence is lower than in Western populations, the Padua Score may overestimate absolute risk while maintaining its ability to discriminate between higher and lower risk groups.
References
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist · Editorial policy
Related Calculators
🧮AUDIT Score Calculator
Calculate audit score with inputs, formulas, and instant results.
🧮Duke Treadmill Score Calculator
Calculate duke treadmill score with inputs, formulas, and instant results.
🧮Revised Geneva Score Calculator
Calculate revised geneva score with inputs, formulas, and instant results.
🧮Diet Risk Score Calculator
Calculate diet risk score with inputs, formulas, and instant results.
🧮Bishop Score Calculator
Calculate bishop score with inputs, formulas, and instant results.
🧮Vterisk Score Calculator in Pregnancy
Calculate vterisk score in pregnancy with inputs, formulas, and instant results.
🧮Apgar Score Calculator
Calculate the Apgar score for newborn health assessment at 1 and 5 minutes after birth.
🧮Menopause Symptom Score Calculator
Score menopause symptom severity using the Menopause Rating Scale questionnaire.